Tag - Soricimed

Developments

MDACC begins dosing pancreatic cancer patients in Phase 1b trial of Soricimed’s SOR-C13

Closely-held Soricimed reported that The University of Texas MD Anderson Cancer Center (MDACC) has begun dosing the first cohort of three late-stage pancreatic cancer patients in its investigator-initiated trial of SOR...

September 24, 2019

Developments

Soricimed, Image Analysis Group to validate SOR-C13 imaging markers

Soricimed Biopharma entered into a strategic alliance with Image Analysis Group for the development of Soricimed’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel. Image...

September 6, 2019

Executive Moves

Soricimed taps industry veteran, Robert Bruce, as CEO

Closely-held Soricimed Biopharma appointed Robert Bruce as CEO, effective immediately, succeeding Paul Gunn, who continues as president. “Soricimed is taking an important step forward at this time and I am excited to...

July 17, 2019

Executive Moves

Soricimed names Vaughn Embro-Pantalony as chairman, Susan Hicks to BOD

Closely-held Soricimed Biopharma named Vaughn Embro-Pantalony, a current director, as chairman and Susan Hicks to its board, both effective immediately. Mr. Embro-Pantalony, who joined Soricimed’s board in March 2018...

September 4, 2018

Tag - Soricimed

MDACC begins dosing pancreatic cancer patients in Phase 1b trial of Soricimed’s SOR-C13

Soricimed, Image Analysis Group to validate SOR-C13 imaging markers

Soricimed taps industry veteran, Robert Bruce, as CEO

Soricimed names Vaughn Embro-Pantalony as chairman, Susan Hicks to BOD

General

More